Tags: La | Jolla | Kidney | Drug

La Jolla Pharma's Kidney Drug Found Effective

Monday, 10 Mar 2014 05:23 PM

La Jolla Pharmaceutical Co. said its lead experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study, sending the company's shares soaring in extended trading Monday.

The company said the trial tested two doses of the drug, codenamed GCS-100, and the lower dose showed an increase in the rate of blood filtering through the kidneys, compared with a placebo.

La Jolla said the lower dose also reduced the levels galectin-3, a protein associated with tissue scarring.

The higher dose did not show a statistically significant increase in the rate of blood filtering or reduction of the levels of protein, compared with a placebo.

"There's a biologic feedback at the higher doses that neutralized the effect of the drug," Chief Executive George Tidmarsh said at an investor conference.

"It could be that if you inhabit galectin-3 too much, there's a feedback loop to start synthesis again. So the higher dose is too high," Wedbush analyst Liana Moussatos said.

La Jolla was likely to conduct another mid-stage study to test doses below the higher dose level to determine the drug's response, Moussatos said.

The drug, if approved, could be a blockbuster chronic kidney disease drug - a large market without any approved treatments, analysts said.

"Even with a modest penetration, we estimate the drug could have over $2 billion in peak sales in 2024, and that's a conservative estimate," Chardan Capital Markets analyst Ling Wang said.

La Jolla said the drug was well-tolerated and there were no serious adverse events in the lower dose group.

There were two serious adverse events each in the placebo group and the higher dose group.

The company said the events in the higher dose group were not related to the drug.

The trial enrolled 121 patients with moderate to severe chronic kidney disease.

Chronic kidney disease is a gradual loss of kidney function, mainly caused by diabetes and high blood pressure. It affects about 26 million adults in the United States, according to the National Kidney Foundation.

La Jolla's shares, which were halted prior to the news, closed at $10.90 on the Nasdaq on Monday. Shortly before 7 p.m. in New York, the shares were up 62 percent at $17.64. Based on the regular closing price, the stock had risen 38 percent since March 5, when La Jolla said it would provide an update on the trial at an investor conference on Monday.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
La Jolla Pharmaceutical Co.said its experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study, sending the company's shares sharply higher in extended trading Monday.
La,Jolla,Kidney,Drug
406
2014-23-10
Monday, 10 Mar 2014 05:23 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved